Clearmind Medicine's CEO, Dr. Adi Zuloff-Shani, was selected as a delegate to the 2026 Federal Policy Summit on Psychedelic Medicine held in Washington, D.C. The summit gathered U.S. lawmakers, federal officials, researchers, and biopharma leaders to discuss advancing psychedelic-derived therapies responsibly. Clearmind is advancing non-hallucinogenic psychedelic treatments with ongoing Phase IIa trials at top institutions like Johns Hopkins and Yale. This participation highlights Clearmind's role in shaping policy and development of novel neuroplastogen-based therapeutics for underserved health issues.
SaintQuant has officially launched its AI-driven quantitative crypto trading platform, offering retail investors easy, no-code access to automated trading strategies. This launch coincides with Bitcoin surpassing $82,000 and record institutional infl...
SpaceX is expected to release its IPO prospectus soon, aiming to raise $70-75 billion and seek a valuation around $1.75 trillion, which would make it one of the most valuable public companies globally. The company's revenue is largely driven by Starl...
The global protective films market is projected to grow from $5.81 billion in 2026 to $7.62 billion by 2031, at a CAGR of 5.6%. Growth is fueled by rising demand for surface protection during manufacturing, transportation, and installation, especiall...
IDenta Corp reported its strongest quarter ever in Q1 2026, with revenues rising to $520,983 from $174,799 in Q1 2025. The company saw significant profit improvements, turning a net loss into a net profit of $29,860. Growth was driven by expanding in...
Auddia Inc. filed an S-4 registration statement with the SEC for its planned merger with Thramann Holdings, which will form McCarthy Finney, managing four AI-focused businesses. The merger is backed by a $12 million financing and awaits SEC review, s...
